Biochemical pharmacology of high dose 1-β-d-arabinofuranosylcytosine in childhood acute leukemia

Cancer Research

Volumn 47, Issue , 1987, Pages 6786-6792

  Avramis, Vassilios I ^a   Biener, Robert ^a   Krailo, Mark ^b   Finklestein, Jerry ^c   Ettinger, Lawrence ^d   Willoughby, Michael ^e   Siegel, Stuart E ^a   Holcenberg, John S ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b CCSG ^*  (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e Princess Margaret Hospital for Children ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE;

ACUTE LEUKEMIA; ADOLESCENT; BLOOD; BONE MARROW; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION;

ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CHILD; CYTARABINE; HALF-LIFE; HUMAN; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC; NEUTROPENIA; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023589415     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Skipper, H. E., Schabel, F. M., Jr., and Willcox, W. S. Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother. Rep., 51:125-165, 1967.
2. Bodey, G. P., Rodriguez, V., McCredie, K. B., and Freireich, E. J. Early consolidation therapy for adults with acute leukemia in remission. Med. Pediatr. Oncol., 2:299-307, 1976.
3. Plunkett, W., Estey, E., Keating, M., and Freireich, E. J. Prognostic potential of Ara-CTP pharmacodynamics during therapy of acute leukemia with high-dose Ara-C. Proc. Am. Soc. Clin. Oncol., 2:28, 1983.
4. Plunkett, W., Iacoboni, S., Estey, E., Danhauser, L., Liliemark, J. O., and Keating, M. J. Pharmacologically directed Ara-C therapy for refractory leukemia. Semin. Oncol., 12:20-30, 1985.
5. Ho, D. H. W. Distribution of kinase and deaminase 1-β-D-arabinofuranosyl-cytosine in tissues of man and mouse. Cancer Res., 33:2816-2820, 1973.
6. Cheng, Y-C., and Cheng, E. H. Enzymatic determinants of the action of cytosine arabinoside (Ara-C). Proceedings of the 13th International Congress on Chemotherapy, 12:21/1-4, 1983.
7. Cheng, Y-C., Domin, B., and Lee, L. S. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochem. Biophys. Acta, 481:481-492, 1977.
8. Momparler, R. L., Brent, T. P., Labitan, A., and Krygier, V. Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol. Pharmacol., 7:413-419, 1971.
9. Hande, R. K., and Chabner, B. A. Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells. Cancer Res., 38:579-585, 1978.
10. Furth, J. J., and Cohen, S. S. Inhibition of mammalian DNA polymerase by the 5'-triphosphate of 1-0-D-arabinofuranosylcytosine and the 5'-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res., 28:2061-2067, 1968.
11. Graham, F. L., and Whitmore, G. F. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5'-triphosphate. Cancer Res., 30:2636-2644, 1970.
12. Momparler, R. Kinetic and template studies with 1-β-D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol. Pharmacol., 8:362-370, 1972.
13. Kufe, D. W., Weichelbaum, R., Egan, E. M., and Fram, R. I. Lethal effects of 1-0-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Mol. Pharmacol., 25:322-326, 1984.
14. Plunkett, W., Hug, V., Keating, M. J., and Chubb, S. Quantitation of 1-β-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-arabinofuranosylcytosine therapy. Cancer Res., 40:588–591, 1980.
15. Liliemark, J. O., Paul, C. Y., Gahrton, G., and Peterson, C. O. Pharmacokinetics of 1-β-D-arabinofuranosylcytosine 5'-triphosphate in leukemic cells after intravenous and subcutaneous administration of 1-β-D-arabinofuranosylcytosine. Cancer Res., 45:2373-2375, 1985.
16. Liliemark, J. O., Plunkett, W., and Dixon, D. O. Relationship of 1-β-D-arabinofuranosylcytosine in plasma to l-β-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high dose 1-β-D-arabinofuranosylcytosine. Cancer Res., 45:5952-5957, 1985.
17. Riva, C. M., and Rustum, Y. M. 1-β-D-Arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response. Cancer Res., 45:6248-6249, 1985.
18. Goldie, J. H., and Goldman, A. J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep., 63:1727-1733, 1979.
19. Momparler, R. L. A model for chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Res., 34:1775-1787, 1975.
20. Stewart, C. D., and Burke, P. J. Cytosine deaminase and the development of resistance to arabinosylcytosine. Nature (Lond.), 233:109-110, 1971.
21. Avramis, V. I., Biener, R., and Holcenberg, J. S. New approaches to overcome drug resistance. In:D. Poplack (Ed.), The Role of Pharmacology in Pediatric Oncology, pp. 97–112. The Netherlands:Martinus Nijhoff, 1987.
22. Goldie, J. H., Goldman, A. J., and Gudauskas, G. A. Rationale for the use of alternating non-gross-resistant chemotherapy. Cancer Treat. Rep., 66:439-449, 1982.
23. 3H]-thymidine for 8 or 10 days. Cancer (Phila.), 25:1237-1260, 1970.
24. Daniel, C., and Wood, F. S. Fitting equations to data. New York:John Wiley and Sons, 1980.
25. Bishop, Y. M. M., Feinberg, S. E., and Holland, P. M. W. Discrete multivariate analysis. Cambridge, MA:MIT Press, 1975.
26. Rustum, Y. M., Slocum, H. K., Wang, G., el al. Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment. Med. Pediatr. Oncol., I(Supply 33-43, 1982.
27. Plunkett W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantar-jian, H., and Keating, M. J. Saturation of 1-β-D-arabinofuranosylcytosme 5'-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabi-nofuranosylcytosine therapy. Cancer Res., 47:3005-3011, 1987.